設為首頁|加入收藏|英文版

總體介紹

首頁 > 廣東省中醫藥科學院 > 總體介紹

惡性腫瘤辨證論治與精準治療研究團隊

2017/7/15 10:50:03字號:T|T

 

惡性腫瘤辨證論治與精準治療研究團隊以全國名老中醫劉偉勝教授為學術顧問,張海波教授為學術帶頭人。團隊與中國科學院北京基因組研究所、美國MD Anderson 癌癥中心、美國UCLA大學、英國Cardiff大學合作,研究內容涵蓋惡性腫瘤的中西醫結合基礎與臨床研究,包括中醫辨證標準化,分子病理學,液體活檢,中醫藥臨床研究,中藥藥理學,基因組學、代謝組學等多學科研究,致力于提高惡性腫瘤中西醫結合治療水平,并推進中醫藥國際化。

Malignant Tumor TCM Syndrome Differentiation and Precision Medicine Research Team is led by professor Haibo Zhang. Professor Weisheng Liu, the National Famous Doctor of TCM, gives academic advices for the researches. This team have cooperation with Beijing Institute of Genomics, Chinese Academy of Science, MD Anderson Cancer Center,UCLA, and Cardiff University. We focus on the basic and clinical researches about malignant tumor, aiming to improve the efficacy of comprehensive treatment combining TCM and western medicine and for malignant tumor, and to go forward for the TCM internationalization. Our researches cover standardization of TCM syndrome differentiation, molecular pathology, liquid biopsy, clinical trials about Chinese medicine, pharmacology of TCM, Genomics, and metabonomics studies and so on.

隊主攻方向 Main direction

1.IIIB/IVNSCLC患者中醫辨證分型與分子病理分型(NGS)、EGFR基因狀態、EGFR-TKIs療效及耐藥之間的基礎與臨床研究。

Basic and Clinical Researches about the relationship between TCM syndrome types and molecular pathological types, EGFR status and efficacy of EGFR-TKIs in NSCLC patients.

基于中醫的“同病異治”理論和西醫的“精準醫學”理念,以IIIB/IV期非小細胞肺癌患者為研究對象,通過分析患者不同的中醫辨證分型與各自分子病理分型間的相關性,建立NSCLC患者宏觀辨證分型與微觀分子分型的網狀模型,同時觀察中醫辨證分型、分子病理分型與療效及預后的關系,從而為中醫的辨證分型提供客觀物質基礎,為傳統中醫理論的現代化提供理論基礎和依據,并建立中醫辨證分型、分子病理分型分布數據庫,為下一步指導中醫治則、治法、用藥及“精準醫學”新藥開發提供前期臨床流行病學數據。通過細胞、動物實驗及臨床觀察的證候演變規律,明確何種治法中藥對EGFR-TKIs具有協同作用,為以后臨床選用合適治則方藥聯合治療NSCLC提供指導原則并為逆轉EGFR-TKIs藥物耐藥提供理論基礎。


According to TCM theory, we may treat patients with same disease using different therapies, which was similar to the concept of Precision Medicine. We enrolled stage IIIB/IV NSCLC patients, analyzed the relationship between the TCM syndrome types and molecular pathological types, in order to establish a network model. We also observed the efficacy and prognosis with different TCM syndrome types and molecular pathological types. According to this data, we may find out the material basis for TCM syndrome types, and provide epidemiological basis for further studies about TCM treatment principles, TCM herbs and Precision new drug researches for NSCLC patients. We also hold cellular and animal studies to prove our previous findings.


2.中醫藥聯合化療對EGFR野生型的IIIB/IV期非小細胞肺癌維持治療研究。

Efficacy of TCM combining with maintenance therapy in stage IIIB/IV NSCLC patients harboring wild-type EGFR gene.

EGFR野生型的IIIB/IV期非小細胞肺癌為研究對象,探討一線常規化療后,中醫藥聯合化療的維持治療作用。同時在治療前對患者中醫“寒”“熱”“瘀”證型進行分層,明確中醫證型與上述藥物療效及生存的關系,以期尋找到一種延緩甚至肺癌進展的新方法,部分解決目前肺癌治療的瓶頸問題。

  We are enrolling Stage IIIB/IV NSCLC patients who harbor wild-type EGFR gene, and will observe the efficacy of TCM combining with maintenance therapy after first line chemotherapy. We also analyze the relationship between TCM syndrome types, including Yin-cold, Yang-heat and blood-stasis, and efficacy of maintenance TCM and chemotherapy. We are trying to find a new way to improve the efficacy for wild-type EGFR NSCLC patients   


3. 腸癌患者中醫辨證分型與分子病理分型、腸道微生物菌群宏/泛基因組相關性的基礎與臨床研究

Basic and Clinical Researches about the relationship between TCM syndrome types and molecular pathological types and gut microbiome/microbiota in colorectal cancer patients

基于中醫證候理論,探討腸癌患者中醫辨證分型與西醫腸道微生物菌群的相關性,尤其是III期腸癌術后患者中藥治療后辨證分型的變化規律和腸道微生物菌群的變化規律,明確何種中藥可以延緩腸癌術后復發,并從腸道微生物菌群宏/泛基因組角度探討中藥治療腸癌的可能機制。

  We are analyzing the relationship between TCM syndrome types and gut microbiome/microbiota, especially the changes in TCM syndrome types and gut microbiome/microbiota after TCM treatments in patients with stage III colorectal cancer after resection. We are trying to find TCM treatments to delay recurrence for these patients, and to reveal the possible mechanism of the TCM efficacy, using gut microbiome/microbiota analysis methods.

 

團隊主要成員 Members of the team

 

學術帶頭人 Academic leader

張海波  主任醫師,教授,醫學博士。廣東省中醫院腫瘤科科主任,博士研究生導師,香港浸會大學臨床教研中心及美國MD.安德森腫瘤中心訪問教授。中國中醫科學院中青年名中醫;廣東省千百十工程人才培養對象;廣東省衛生系統“青年崗位能手”。美國腫瘤臨床協會(ASCO)委員;中國腫瘤臨床協會(CSCO)青年委員;中華中醫藥學會(CACM)腫瘤青年專業委員會副主任委員;中國老年腫瘤康復專業委員會(CGOS)常委;廣東省醫院協會分子靶向治療專業委員會副主任委員;廣東省中醫腫瘤康復與治療專業委員會副主任委員;廣東省中醫腫瘤專業委員會常委,廣東省抗癌協會(GDACA)靶向與個體化治療專業委員會常委,肺癌、大腸癌專業委員。國家自然基金項目評審專家;ESMO官方雜志Annals of oncology中文版、中醫雜志、重慶醫學、疑難病雜志等知名雜志編委。近年主編及參編腫瘤專著4部,在國內外期刊發表論文40余篇。目前主持國家自然基金科研項目1項;廣州市科創委健康醫療協同創新重大專項1;國際合作項目——加拿大TerryFox癌癥基金2項;衛生部、民政部科研課題各1項;廣東省科技廳科研課題2項;CSCO同輝基金1項;吳階平基金會腫瘤專項基金課題1項;參與國家“十五” “十一五”科技攻關、衛生部、上海市、廣東省以及廣州中醫藥大學等各級科研課題10余項。獲廣州中醫藥大學科技進步二等獎2項。主要從事肺癌、胃腸癌等惡性腫瘤的中西醫臨床與臨床基礎研究。

Professor Haibo Zhang, chief physician, M.D.&Ph.D, MD student supervisor, is the chief of Oncology Department of Guangdong Provincial Hospital of Chinese Medicine. He specializes in helping cancer patients by combining TCM and Western approaches, especially for those with lung cancer and colorectal cancer. He focuses on the basic and clinical studies about combination of TCM and Western medicine in cancer. He worked as a visiting scholar in the Hong Kong Yan-chai Hospital and the Hong Kong Baptist University Clinical Research Center in 2007 and 2008, and is now working as a visiting scholar in MD Anderson cancer center. He received the award as Youth Famous TCM Doctor from China Academy of Chinese medical Science, the training award from Guangdong Province’s “Thousand-Hundred-Ten” Program, the award as Youth Skilled Expert from Guangdong Provincial Health System. Currently, he is a member of  American Society of Clinical Oncology (ASCO), a youth member of Chinese Society of Clinical Oncology (CSCO), a vice chairman of Youth Oncologists of China Association of Chinese Medicine (CACM), a standing member of Chinese Geriatric Oncology Society (CGOS), a vice chairman of the Molecular Targeted Therapy Committee of Guangdong Provincial Hospital Association, a vice chairman of the Guangdong Provincial TCM Tumor Rehabilitation and Treatment Committee,a standing member of Guangdong TCM Oncology Committee, a standing member of Targeted and Personal Therapy Committee and an expert member of Lung cancer and Colorectal Cancer Committee of Guangdong Provincial Anti-cancer Association (GDACA). He is also a reviewer expert of Natural Science Foundation of China (NSFC), an editorial member of the Famous Journals, such as Chinese Edition of Annals of Oncology, Journal of Traditional Chinese Medicine, Chongqing Medical Journal, Journal of Difficult Diseases, and so on. He co-edited and was a book chapter contributor for 4 college text books. He published more than 40 papers. Currently, he is in charge of many research projects, including those funded by Natural Science Foundation of China (NSFC), Major Projects of Collaborative Innovation in Health Care of Science and Technology Program of Guangzhou, Canadian Terry Fox Foundation, Chinese Ministry of Civil Affairs Grant, Chinese Ministry of Health Grant, Science and Technology Department of Guangdong Province Foundation, CSCO Foundation, Wu Jieping Foundation, and so on. He also worked as principle a co-investigator in many other research projects, including those funded by the National “10th Five-year" and 11th Five-year Technology Support Program. He has won the second prize of Science and Technology Advance twice from Guangzhou University of TCM.


學術骨干Academic backbone

朱燕娟  醫學碩士,主治醫師,腫瘤整合醫學學會(SIO)委員。主持吳階平醫學基金課題1項,參與惡性腫瘤相關國家級、省部級、廳局級課題6項,參編腫瘤專著1部,發表SCI論文多篇。

Yan-juan Zhu, Master of Medicine, Chief physician, is a member of Society of Integrative Oncology (SIO). She is now chairing 1 research project Funded by Wu Jieping Foundation, and participating in 6 projects Funded by national, provincial and city level Fundation. She was a book chapter contributor for 1 college text book. She has also published a number of academic articles indexed by SCI.

首頁|網站地圖|法律申明|友情鏈接|招聘信息|供應商管理|名老中醫學術交流|中醫健康管理|中醫醫案管理 |知識管理|在線考試
澳门威尼斯人赌城官网